Pfizer Is Back In The CTLA-4 Game Via Pact With OncoImmune
Executive Summary
Pfizer bought an option to license OncoImmune’s anti-CTLA-4 antibody ONC-392 five years after out-licensing its own internal candidate tremelimumab to AstraZeneca following a study failure.
You may also be interested in...
Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Golden Meditech and MD Anderson establish startup focused on umbilical cord blood-derived T-regulatory therapies. Bayer and Evotec sign their second collaboration in four years, this time focused on renal disease.
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
Pfizer has seven immuno-oncology drugs in the clinic and an ambition to be the first drug maker to bring a PD-1/OX40/4-1BB triplet regimen into the clinic late this year or early next.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.